Legal entity
regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Peter Marks, the most common co-covered peer. Source depth averages 8 original sources per story, versus 3.1 across the same-window beat baseline.
Last mentioned: Feb 24, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Peter Marks, the most common co-covered peer. Source depth averages 8 original sources per story, versus 3.1 across the same-window beat baseline. Their average consequence score of 8 runs above the beat's 7.2 for that window. We currently track 1 Legal story that mention Center for Biologics Evaluation and Research (CBER), all published on February 23, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 20 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Center for Biologics Evaluation and Research (CBER). Shared-story counts are live from our verified record — not editorial picks.
Expedited Pathway Formalized
FDA announces the formal implementation of quicker paths for gene therapy via surrogate endpoints.
START Pilot Launch
FDA initiates a pilot program for Support for clinical Trials Advancing Rare disease Therapeutics.
CBER Reorganization
The Office of Tissues and Advanced Therapies is elevated to a 'Super Office' to handle CGT volume.
Luxturna Approval
FDA approves the first gene therapy for an inherited disease, setting the initial regulatory precedent.
The U.S. Food and Drug Administration has established a streamlined regulatory pathway to expedite the development and review of gene therapies. This initiative focuses on leveraging surrogate endpoints and platform technologies to bring life-altering treatments for rare diseases to market faster.
Center for Biologics Evaluation and Research (CBER) is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
